Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.07 - $145.42 $14.2 Million - $17.3 Million
-119,000 Reduced 56.8%
90,500 $10.8 Million
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $22.9 Million - $27.4 Million
186,500 Added 810.87%
209,500 $29.9 Million
Q1 2024

May 15, 2024

SELL
$102.11 - $135.92 $1.17 Million - $1.56 Million
-11,500 Reduced 33.33%
23,000 $2.95 Million
Q4 2023

Feb 14, 2024

BUY
$87.78 - $105.45 $2.73 Million - $3.28 Million
31,100 Added 914.71%
34,500 $3.57 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $154,598 - $339,218
1,700 Added 100.0%
3,400 $309,000
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $265,166 - $293,505
1,700 New
1,700 $275,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.